News U10

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters.

The project, Position-II (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), reduce current production costs and break existing monopolies, has been submitted to the Call for Electronic Components and Systems for European Leadership (ECSEL)- Horizon 2020, with a duration of three years -starting on 1/6/18- and with a budget of over €41M, (€10.4M-financed by European Union)

The objective of the participation of JUMISC in Position-II is to develop new catheters that, in combination with hydrogels and cell therapy, will have a regenerative effect to stimulate the recovery of cardiac areas damaged by heart attacks. NANBIOSIS U10. Drug Formulation, of CIBER-BBN, at UPV-EHU, coordinated by José Luis Pedraz and Jsús Ciriza, will microencapsulate the cells to be test and administered in porcine model at the JUMISC to validate the designed catheter.

The kick-off of the Eurpean project under Grant Agreement Ecsel-783132- POSOTION II 2017-IA took place on June 5 to 7 in Rotterdam, representatives of the NANBIOSIS-ICTS Steering Committee, unit 10 and unit 24 were present.

• Read More

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers.

The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of the Basque Country, led by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, which participates, through the CIBER BBN and the ICTS Nanbiosis, in the Drive Project focused on pancreatic cell transplantation and the development of biomaterials and new surgical devices that improve the transplantation and survival of insulin-producing pancreatic islets for the treatment of diabetes.

Dr. Pedraz explained for EIBT.eus Radio euskadi the aim of the DRIVE project: the transplantation of the cells of the pancreas, which consists of isolating the insulin-producing cells from a donor’s pancreas and implanting them in the patient with daibetes type I, not directly, but introduced into an artificial bio-pancreas by minimal invasive surgery . “Nowadays– explains Dr. Pedraz- obtaining pancreatic cells from stem cells or IPS cells is a not yet controlled process but it is an alternative source of insulin-producing cells. In the DRIVE project the most priority objective is to take the donor cells and introduce them into a device that will allow the patient to produce and release insulin in a more physiological way. In a second phase, it is intended to use differentiated insulin producing cells from the patient’s own cells, thus alleviating the shortage of donors”.

• Read More

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with diabetes and relatives who want to participate. “One of the objectives of this meeting is to better understand the expectations of people with diabetes and their doubts about the treatment of that disease. By giving us their opinion, they will help us to adapt the DRIVE project to their needs“, explained the organization.
The event is organized by the NanoBioCel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, directed by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, who participates in the DRIVE project through the CIBER BBN and the ICTS Nanbiosis, the only Spanish group in the project .
Admission is free and can be obtained at: https://www.ticketea.com/entradas-conferencia-drive-patient-panel/

• Read More

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, the CIBER-BBN and the CIBERES.

The objective of this event, structured in sessions of presentations and scientific debates about the types of technologies addressed, was to promote the exchange of ideas and scientific knowledge with the aim of generating new collaborations among the CIBER research groups such as participation in transversal projects or the development of cutting-edge technologies.

NANBIOSIS was represented by Pablo Laguna (Unit 27, High Performance Computing), Laura Lechuga (Unit 4, Biodeposition and Biodetection Unit), José Luis Pedraz (Unit 10, Drug Formulation) and Rosa Villa (Unit8, Micro – Nano Technology Unit)

• Read More

Gene therapy in pseudohypoparathyroidism

In 1942, Albright and colleagues described the first hormone resistance syndrome, which they called pseudohypoparathyroidism (PHP) (1), patients had a specific phenotype consisting of short stature, central obesity, round face, short neck and brachydactyly, which is what that today we know like Albright Hereditary Osteodystrophy (AHO, Albright Hereditary Osteodystrophy).

Nanobiocel research group, coordinator of NANBIOSIS U10. Drug Formulation, is working on the project “Gene therapy in pseudohypoparathyroidism: experimental development based on CRISPR / CAS9 and non-viral vectors“. The objective of the project is to design and validate the ex vivo gene therapy protocol for the correction of known mutations in the GNAS gene, causing pseudohypoparathyroidism (PHP) type 1A and pseudoPHP, through the following operational objectives: (1) Validation of the model lymphoblasts (immortalized or not) for the application of gene therapy; (2) CRISPR / Cas trial design and vehicularization in non-viral vectors; (3) Identification and characterization of off-target insertions (if any) and (4) Confirmation through functional studies of the correct functioning of the protein obtained from the modified gene.

The project will be carried out by the following research groups: BioAraba of Molecular Epigenetics in rare diseases, led by Dr. Guiomar Pérez de Nanclares, in the OSI Araba – Txagorritxu, the group Nanobiocel, led by Jose Luis Pedraz at UPV/EHU, this group is part of CIBER-BBN and ICTS NANBIOSIS and the group of Professor Cesar Martin, Biofisika Institute (UPV/EHU, CSIC).

• Read More

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies.

The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the aim of generating new collaborations for participation in cross-cutting projects and the development of border technologies. The content of the forum, centered on the type of technology and possibilities it offers, is structured in a program of lectures and scientific debates whose final objective is the discussion and the joint generation of ideas. This first edition of the forum will be focused on Gene Therapy, Nanotechnologies and Omic Technologies-Big Data.

Some Units of NANBIOSIS will participate:

José Luis Pedraz, Scientific Director of Unit 10 Drug Formulation, will speak of “Development of non-viral vectors for gene therapy“
Laura Lechuga, Scientific Director of Unit 4 Biodepositon and Biodetection, will talk about “Nanodispositive biosensors for advanced clinical diagnosis
Rosa Villa, Scientific Director of Unit 8 Micro–Nano Technology, Ramón Martínez, Scientific Director of Unit 26 NMR Biomedical Applications II and Esther Pueyo, researcher of U27 High Performance Computer will moderate the sessions.

Programme and registration details

• Read More

NANBIOSIS Unit 10 of Drug Formulation participates in the European Project Position II

Nanobiocel, the CIBER-BNN – UPV-EHU group, led by José Luis Pedraz, Scientific Director of NANBIOSIS-ICTS U10 “Drug Formulation Unit” participates in the Position II European project, coordinated by Philips Electronics Nederland.

The project, funded through the Horizon 2020 call with a global budget of more than 50 million euros, will be developed during three years with the participation of 48 partners. Its general objective is to innovate in the production processes in the field of health to obtain state-of-the-art catheters. It will also include innovative treatments, such as cell therapy, which guide small capsules with cells with a regenerative effect to stimulate the recovery of damaged cardiac areas during the infarction.

The Nanobiocel group will be responsible for carrying out the formulation of the cells in hydrogels, for administration through the catheter at the cardiac level, for the regeneration of heart tissue.

In the development of the project, NANBIOSIS U10 “Drug Formulation Unit ” will participate. This Unit, located in the Faculty of Pharmacy of the UPV / EHU, has the capacity to design and evaluate classic dosage forms and new forms of biotechnological drugs, DNA, RNA and vaccines, using different methodologies based on micro and nanomedicine. This last methodology, based on the microencapsulation of cells, peptides, proteins and, in general, of biotechnological products, as well as the development and design of non-viral vectors for gene therapy, is one of the greatest singularities of this unit. It has the most advanced equipment for micro and nanoencapsulation.

The Eurpean project under Grant Agreement Ecsel-783132- POSOTION II 2017-IA, seeks to reverse the nowadays obsolete production of catheters (in the last decade there have been no innovations in this field). This justifies, from a business point, the investment in new R & D lines. In addition, it will introduce open technology platforms to increase miniaturization, the integration of electronics, wireless communications and their encapsulation. These technology platforms will renew catheter-based interventions, improving performance and reducing current production costs. It also seeks to break the current monopoly of US companies in the development and production of smart catheters.

• Read More

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the first groups/companies meeting organized by Nanbiosis, in which about 70 B2B meetings were held.

The meeting brought together about 40 participants from 14 research groups (from the CIBER-BBN and the CCMIJU) and 10 companies, which discussed the latest advances in the research lines developed by the groups and platforms of Nanbiosis and on the needs and demands of the industry in smart biomaterials and devices for targeted drug delivery and regenerative medicine.

Jesus Izco, Coordinator of Nanbiosis, presented the new “Cutting-Edge Biomedical Solutions“, soon available on the ICTS website. These are integrated solutions to advanced challenges in nanomedicine, biomaterials, medical device, and diagnostic that can be developed by several units under a one-stop shop model, optimized with the experience and scientific and technical knowledge of the research groups of excellence that manage the involved units. Some of the Cutting-edge biomedical solutions presented in the meeting were preclinical validation of biomaterials, mechanical and surface characterization, biocompatibility and studies of biofilm formation and infections.

The CIBER-BBN prsentations were: “Instructive materials for regenerative medicine” by Miguel Ángel Mateos (NANBIOSIS U5 IP: Elisabeth Engel); “Molecular biomaterials for drug delivery and biomedical applications” byNathaly Veronica Segovia (NANBIOSIS U6 / IP Jaume Veciana and Nora Ventosa); “Advances with micro-nano technologies for in vitro devices and point of care” by Rosa Villa (NANBIOSIS U8 ); “Development of new dosage forms for advanced therapies based on new biomaterials” by José Luis Pedraz (NANBIOSIS U10); “Contact lenses functionalized for the prevention of corneal infections” by Jordi Esquena (NANBIOSIS U12 / IP Carlos Rodríguez); “Combined in-silico and in-vitro models of the cell microenvironment and drug delivery effects in cancer and tissue engineering applications” by Fany Peña (NANBIOSIS U13 / IP Miguel Á. Martínez); “Surface of the biomaterial: the first contact with our body” by Marisa González (NANBIOSIS U16 ); “Use of biomaterials for the repair of soft tissue defects” by Bárbara Pérez Khöler (NANBIOSIS U17 / IP J M. Bellón and Gemma Pascual); “Controlled release systems based on mesoporous materials with molecular doors for applications in therapy and diagnosis” by Ramón Martínez Máñez (NANBIOSIS U26); “New intelligent devices and biomaterials for the treatment of pathologies of the retina and the nervous system” (Eduardo Fernández); and “Near-infrared responsive scaffolds for biomedical applications” (Nuria Vilaboa).

On the part of the CCMJU, the presentations were the following: “Application of Mesenchymal Stem Cells in preclinical models for surgical and cardiovascular research” by Javier García Casado (NANBIOSIS U14); “Regenerative medicine in animal models of cutaneous healing and diabetic models” by Beatriz Moreno (NANBIOSIS U19); “Preclinical studies of biomaterials” by Idoia Díaz-Güemes (NANBIOSIS U21 /IP: FM Sánchez Margallo); “Porcine model of myocardial infarction as a translational research platform in regenerative medicine” by Verónica Crisóstomo (NANBIOSIS U24).

In the turn of the companies, they presented some collaboration opportunities AJL, i-Vascular, Praxis Pharmaceutical, Technical Proteins Nanobiotechnology and REGEMAT 3D; and they also participated in the Rovi, Viscofan, Biomag and Biogelx Laboratories forum.

These meetings, where links are established between research groups and companies, address issues of business and scientific interest, allowing direct contacts between researchers and business managers.

• Read More

Cryopreservation of stem cells

Scientific Reports of the Nature Publications Group has recently published the article ‘Cryopreservation of human mesenchymal stem cells in an allogeneic bioscaffold based on platelet rich plasma and synovial fluid’. This research is part of the doctoral thesis of Haritz Gurruchaga, belonging to the NanoBioCel group of CIBER-BBN and UPV / EHU, which is focused on the optimization of the storage processes of encapsulated cells through slow cryopreservation. The thesis is being co-directed by José Luis Pedraz and Jesús Ciriza, Scientific Director and Scientific Coordinator of NANBIOSIS Unit 10 Drug formulation.

The work is focused on the optimization of the storage processes of encapsulated cells through slow cryopreservation. Mesenchymal stem cells are being increasingly used for the treatment of various diseases

For further information

Article of reference:

Haritz Gurruchaga, Laura Saenz del Burgo, Ane Garate, Diego Delgado, Pello Sánchez, Gorka Orive, Jesús Ciriza, Mikel Sánchez, José Luis PedrazCryopreservation of Human Mesenchymal Stem Cells in an Allogeneic Bioscaffold based on Platelet Rich Plasma and Synovial FluidScientific Reports 7, Article number: 15733 (2017) DOI: 10.1038/s41598-017-16134-6

• Read More

Therapeutic approaches with CRISPR for albinism

Preclinical Development of CRISPR- based non-viral therapeutic approaches in existing cellular and animal models of Albinism, (NanoCripsAlbino Therapy) is a multidiciplinar project to study ways to bring genetic editing tools to target cells to develop therapeutic strategies that can be used to treatment. The project, participated by Lluís Montoliu (CIBERER) and José Luis Pedraz (CIBER-BBN) and will financed by the Internationalization Platform of CIBER-BBN/ER/RES- with € 50000.

José Luis Pedraz is the Scientific Director of NANBIOSIS Unit 10 Drug formulation and PI of the CIBER-BBN NANOBIOCELL group, experst in de development of micro and nanoparticles to formulate new active principles based on peptides, proteins… and coming from new technologies such as Crispr/Cas technology. Specially in this project as Dr. Pedraz explains “We will contribute with our know-how in the development of non-viral particles based on lipid components to attach them to the CRISPR system and release them taking them to the target cell to correct the genetic defect”

Researchers have carried out a video to expose the objectives of the new project.

• Read More

You are here : Home / News U10 (Page 5)